v3.20.1

Segment information | 12 Months Ended
--- | ---
Dec. 31, 2019
Segment information |
Segment information | 5. Segment information There are two reportable segments, R&D and fee-for-service business. Segment information for year 2019 (Euro, in thousands)
|  | R&D |  | Fee-for-services |  | Inter-segment elimination |  | Group
External revenue |  | € | 834,901 |  | € | 10,084 |  |  |  |  | € | 844,985
Internal revenue |  |  |  |  |  | 6,742 |  | € | (6,742) |  |  |
Other income |  |  | 50,905 |  |  | — |  |  |  |  |  | 50,905
Revenues & other income |  |  | 885,806 |  |  | 16,826 |  |  | (6,742) |  |  | 895,890
Segment result |  |  | 407,464 |  |  | 1,125 |  |  |  |  |  | 408,589
Unallocated expenses (1) |  |  |  |  |  |  |  |  |  |  |  | (38,297)
Operating income |  |  |  |  |  |  |  |  |  |  |  | 370,292
Financial (expenses)/income |  |  |  |  |  |  |  |  |  |  |  | (220,233)
Result before tax |  |  |  |  |  |  |  |  |  |  |  | 150,060
Income taxes |  |  |  |  |  |  |  |  |  |  |  | (214)
Net income |  |  |  |  |  |  |  |  |  |  | € | 149,845
| (1) |  | The unallocated expenses of €38,297 thousand comprise warrant costs.
Segment information for year 2018 (Euro, in thousands)
|  | R&D |  | Fee-for-services |  | Inter-segment elimination |  | Group
External revenue |  | € | 278,666 |  | € | 10,170 |  |  |  |  | € | 288,836
Internal revenue |  |  |  |  |  | 8,508 |  | € | (8,508) |  |  |
Other income |  |  | 29,000 |  |  | 9 |  |  |  |  |  | 29,009
Revenues & other income |  |  | 307,666 |  |  | 18,687 |  |  | (8,508) |  |  | 317,845
Segment result |  |  | (19,734) |  |  | 1,751 |  |  |  |  |  | (17,983)
Unallocated expenses (1) |  |  |  |  |  |  |  |  |  |  |  | (26,824)
Operating loss |  |  |  |  |  |  |  |  |  |  |  | (44,807)
Financial (expenses)/income |  |  |  |  |  |  |  |  |  |  |  | 15,598
Result before tax |  |  |  |  |  |  |  |  |  |  |  | (29,209)
Income taxes |  |  |  |  |  |  |  |  |  |  |  | (50)
Net loss |  |  |  |  |  |  |  |  |  |  | € | (29,259)
| (1) |  | The unallocated expenses of €26,824 thousand principally comprise of €26,757 thousand of warrant costs.
Segment information for year 2017 (Euro, in thousands)
|  | R&D |  | Fee-for-services |  | Inter-segment elimination |  | Group
External revenue |  | € | 118,262 |  | € | 8,825 |  |  |  |  | € | 127,087
Internal revenue |  |  |  |  |  | 5,104 |  | € | (5,104) |  |  |
Other income |  |  | 28,815 |  |  | 15 |  |  |  |  |  | 28,830
Revenues & other income |  |  | 147,077 |  |  | 13,945 |  |  | (5,104) |  |  | 155,918
Segment result |  |  | (73,610) |  |  | 86 |  |  |  |  |  | (73,524)
Unallocated expenses (1) |  |  |  |  |  |  |  |  |  |  |  | (16,278)
Operating loss |  |  |  |  |  |  |  |  |  |  |  | (89,802)
Financial (expenses)/income |  |  |  |  |  |  |  |  |  |  |  | (25,705)
Result before tax |  |  |  |  |  |  |  |  |  |  |  | (115,507)
Income taxes |  |  |  |  |  |  |  |  |  |  |  | (198)
Net loss |  |  |  |  |  |  |  |  |  |  | € | (115,704)
| (1) |  | The unallocated expenses of €16,278 thousand principally comprise of €16,536 thousand of warrant costs.
Segment assets and liabilities are not information being provided to the chief operating decision maker on a recurring basis. This information is therefore not disclosed in our segment information. GEOGRAPHICAL INFORMATION In 2017, 2018 and 2019, our operations were mainly located in Belgium, Croatia, France and the Netherlands. Following table summarizes the revenues by destination of customer:
|  | Year ended December 31,
|  | 2019 |  | 2018 |  | 2017
|  | (Euro, in thousands)
North America |  | € | 795,605 |  | € | 117,609 |  | € | 82,050
Europe |  |  | 49,018 |  |  | 171,113 |  |  | 45,037
Asia Pacific |  |  | 362 |  |  | 114 |  |  | —
Total |  | € | 844,985 |  | € | 288,836 |  | € | 127,087
Following table summarizes the revenues by major customers:
|  | Year ended December 31,
|  | 2019 |  | 2018 |  |  | 2017
Spilt up of revenues by major customers |  | (Euro, in thousands) |  | % |  | (Euro, in thousands) |  | % |  | (Euro, in thousands) |  | %
Gilead: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
North America (1) |  | € | 793,873 |  | 94% |  | € | 116,640 |  | 40% |  | € | 80,687 |  | 63%
Europe (1) |  |  | (4,570) |  | -1% |  |  | 7,793 |  | 3% |  |  |  |  |
AbbVie: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Europe |  |  | 26,356 |  | 3% |  |  | 89,936 |  | 31% |  |  | 34,049 |  | 27%
Novartis: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Europe |  |  | 19,177 |  | 2% |  |  | 55,218 |  | 19% |  |  |  |  |
Les Laboratoires Servier: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Europe |  |  | — |  | 0% |  |  | 9,000 |  | 3% |  |  | 67 |  | 0%
Total revenues from major customers |  | € | 834,836 |  | 99% | € |  | 278,587 |  | 96% |  |  | 114,804 |  | 90%
| (1) |  | Following the contract amendment, the revenue recognized for filgotinib for the year ended December 31, 2019, included a negative catch-up effect on closing date of €245.9 million resulting from the decrease in the percentage of completion applied to previously received upfront and milestones for that program.
As of December 31, 2019, we held €203 million of non-current assets (€110 million in 2018; €89 million in 2017) distributed as follows:
| · |  | Belgium: €133 million (€64 million in 2018; €47 million in 2017)
| · |  | France: €54 million (€36 million in 2018; €34 million in 2017)
| · |  | Croatia: €7 million (€5 million in 2018; €4 million in 2017)
| · |  | The Netherlands: €8 million (€4 million in 2018; €4 million in 2017)
| · |  | Switzerland: €1 million (nil in 2018 and 2017)
The increase in non-current assets in 2019 as compared to 2018 was mainly explained by (i) an increase in property, plant & equipment explained by new acquisitions in 2019 but also by the recognition of right-of-use assets following the adoption of IFRS 16 Leases, (ii) an increase in intangible assets due to new acquisitions and capitalization of contract costs linked to the collaboration agreement with Gilead, and (iii) an increase in non-current R&D incentives receivables (see note 16).

X
- Definition The entire disclosure for operating segments. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 8 -IssueDate 2019-01-01 -Section Disclosure -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2019-en-r&doctype=Standard&dita_xref=IFRS08_g20-24_TI -URIDate 2019-03-27 + Details
Name: | ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory
Namespace Prefix: | ifrs-full_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | ifrs-full_DisclosureOfOperatingSegmentsAbstract
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration